Skip to main content
NovartisIn development

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis initiated a second Phase 2 clinical study evaluating the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in patients with active moderate to severe psoriatic arthritis.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study This is the second of multiple studies planned to evaluate MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with active moderate to severe psoriatic arthritis (PsA). The study follows the Phase 2 trial in Sjögren's disease initiated in August and is part of a global exclusive development and commercialization license agreement between Monte Rosa and Novartis to advance VAV1 MGDs, including MRT-6160 (DDY391). In connection with the first patient visit of the study, Monte Rosa will receive a $37.5 million milestone payment from Novartis. "This Phase 2 study will assess MRT-6160 in participants with active moderate to severe psoriatic arthritis, a disease with...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
MRT-6160
Takes effect
Oct 28, 2026

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 28, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5f86e1cc-b52a-82e6-cd20-2b77f6cfa477 returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "5f86e1cc-b52a-82e6-cd20-2b77f6cfa477",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T11:00:00+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/28/3390005/0/en/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-second-phase-2-clinical-study-initiation-for-vav1-directed-molecular-glue-degrader-mrt-6160-ddy391.html",
    "title": "Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)",
    "excerpt": "Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study This is the second of multiple studies planned to evaluate MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with active moderate to severe psoriatic arthritis (PsA). The study follows the Phase 2 trial in Sjögren's disease initiated in August and is part of a global exclusive development and commercialization license agreement between Monte Rosa and Novartis to advance VAV1 MGDs, including MRT-6160 (DDY391). In connection with the first patient visit of the study, Monte Rosa will receive a $37.5 million milestone payment from Novartis. “This Phase 2 study will assess MRT-6160 in participants with active moderate to severe psoriatic arthritis, a disease with...",
    "product": "MRT-6160",
    "summary": "Novartis initiated a second Phase 2 clinical study evaluating the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in patients with active moderate to severe psoriatic arthritis.",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/20ed9999-454a-4e2a-aabc-217270a87d2d",
    "confidence": 0.95,
    "product_data": {
      "name": "MRT-6160",
      "full_text": "VAV1-directed MGD MRT-6160 (DDY391)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-28T11:00:00Z",
    "effective_date": "2026-10-28",
    "article_sentence": "Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 (DDY391) in people living with active moderate to severe psoriatic arthritis (PsA)."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.